Drug Management of Rheumatoid Arthritis in Covid-19 Context : Impact on Therapeutic De-escalation

NCT04393233 | Completed

• 1 other identifier: RHUMACOVID ( 29BRC20.0110)
• Study Type: observational
• Target: 300
• Locations: 1 country
• Sites: 1

Brief Summary

The current situation of Sars-Cov-2 pandemic generates fears in the general population. Among patients receiving long-term immunomodulatory drugs, especially in the context of auto-immune diseases, there may be legitimates interrogations about the appropriateness of continuing treatment, without modification, in the current context. Most patients with Juvenile Rheumatoid Arthritis benefit from long-term immunmodulatory therapy (DMARD - disease modifying anti-rheumatic drug), more or less combined with regular use of non-steroidal anti-inflammatory drugs (NSAIDs) or corticosteroids.The present study will characterize this issue by defining the proportion of patients whose usual treatment of Rheumatoid Arthritis has been modified in relation to the actual sanitary crisis.

Conditions

Rheumatoid Arthritis; COVID

Outcome Measures

Primary Outcomes (1)

• Reduction or discontinuation of the DMARD therapy in relation to the Covid-19 sanitary crisis

  Reduction or discontinuation of treatment with sDMARD, bDMARD or tsDMARD

  1 Day

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Rheumatoid arthritis patients with ongoing DMARD therapy.

You may qualify if:

• Rheumatoid arthritis satisfying ACR/EULAR criteria
• Ongoing DMARD therapy

You may not qualify if:

• Inhability to consent

Sponsors & Collaborators

• University Hospital, Brest: lead

Study Sites (1)

CHRU de Brest

Brest, 29609, France

Location

MeSH Terms

Conditions

Arthritis, Rheumatoid

Condition Hierarchy (Ancestors)

Arthritis; Joint Diseases; Musculoskeletal Diseases; Rheumatic Diseases; Connective Tissue Diseases; Skin and Connective Tissue Diseases; Autoimmune Diseases; Immune System Diseases

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 22, 2020
• First Posted: May 19, 2020
• Study Start: April 23, 2020
• Primary Completion: August 23, 2020
• Study Completion: August 23, 2020
• Last Updated: August 9, 2024

Record last verified: 2020-04

Data Sharing

• IPD Sharing: Will share
• Shared Documents: STUDY PROTOCOL
• Time Frame: Data will be available beginning one month and ending five years following the end study
• Access Criteria: Data access requests will be reviewed by the internal committee of Brest UH. Requestors will be required to sign and complete a data access agreement.

Locations

FR (1)